An Extension to Assess the Effect of Expanded Dialysis on Patient Reported Symptoms Using LEVIL
NCT06032208
Recruiting
Investigators know that many patients who are on dialysis suffer from burden of unwanted symptoms, which can affect quality of life. The understanding and treatment of symptom burden by healthcare providers is limited and should be recognized as a high priority in the care of the dialysis population. In this study, the investigators will be assessing symptom burden using the London Evaluation of Illness "LEVIL," an application based platform where patients self-report their symptoms with one to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: Victoria Hospital, London Health Sciences Centre, London, Ontario +1 locations
Conditions: End Stage Renal Disease
Register for Updates
Sentinel lympH Node Biopsy With Indocyanine Green in Breast Cancer After NEoadjuvant Chemotherapy (SHINE)
NCT06085274
Recruiting
This is a prospective, open-label, within-patient clinical trial to determine the accuracy of Indocyanine green (ICG) guided sentinel lymph node biopsy (SLNB) compared to the standard dual-tracer SLNB in breast cancer patients who have had chemotherapy as a first treatment using a non-inferiority design. Patients with operable breast cancer treated with chemotherapy and eligible for SLNB will be included in the study. During surgery, ICG will be injected and used to identify fluorescent sentine... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/04/2025
Locations: University Health Network, Toronto, Ontario
Conditions: Breast Cancer
Register for Updates
Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) for Inflammation and Depression Following SCI
NCT06493071
Recruiting
Spinal cord injury (SCI) has been shown to be associated with impairment to the autonomic nervous system in the form of reduced activity of a key nerve known as the vagus nerve. As the vagus nerve has an important role in regulating inflammation and is associated with depression, it may represent a key mechanism which contributes to chronic inflammation and depression following SCI. A technique known as transcutaneous auricular vagus nerve stimulation (taVNS) can stimulate the vagus nerve non-i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: Parkwood Institute, St Joseph's Health Care London, London, Ontario
Conditions: Spinal Cord Injury, Depression
Register for Updates
Doxycycline to Protect Heart Muscle After Heart Attacks
NCT03508232
Recruiting
Current medical treatment allows more people to survive heart attacks than in the past. However, some of the survivors suffer heart disease and require hospitalization later on. The causes behind this heart disease (heart failure) after a heart attack are poorly understood. Matrix metalloproteinase 2 (MMP-2) is a protein that cuts other proteins into pieces, and is activated in heart muscle when there is a heart attack. MMP-2 causes heart injury when the blood flow to the heart is restored afte... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Royal Alexandra Hospital, Edmonton, Alberta
Conditions: ST Segment Elevation Myocardial Infarction, Heart Failure
Register for Updates
Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis
NCT04562389
Recruiting
This is a global, multicenter, 2-part study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve myelofibrosis (MF) participants. The study will be conducted in two phases: Phase 1 (open-label) and Phase 3 (double-blind). Phase 1 (enrollment completed) was an open-label evaluation of the safety and recommended Phase 2 dose (RP2D) of selinexor in combination with ruxolitinib and included a dose escalation using a standard 3+3 design (Phase 1a)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: UAB Division of Hematology/Oncology, Birmingham, Alabama +148 locations
Conditions: Myelofibrosis
Register for Updates
De-Adoption of Beta-Blockers in Patients With Stable Ischemic Heart Disease
NCT05081999
Recruiting
Patients with heart disease are often prescribed many medications and these patients may experience drug interactions or negative drug related side effects. With newer medications and treatments available, it is not well known whether older drugs, such as beta-blockers, are still an effective and safe option for treating heart disease. Some evidence suggests beta-blockers should be continued, whereas other evidence suggests beta-blockers might cause unnecessary harm. The study hopes to determine... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
02/03/2025
Locations: University of Alberta Hospital, Edmonton, Alberta
Conditions: Stable Ischemic Heart Disease, Coronary Artery Disease, Beta-blocker Therapy
Register for Updates
Dialyzing Wisely - Improving the Delivery of Acute Renal Replacement Therapy to Albertans
NCT05186636
Recruiting
Implementation of an evidence-based and best practices acute RRT pathway aiming to decrease acute RRT program and healthcare systems costs while improving important patient-reported outcomes.
Gender:
ALL
Ages:
All
Trial Updated:
02/03/2025
Locations: Peter Lougheed Centre, Calgary, Alberta +14 locations
Conditions: Acute Renal Injury
Register for Updates
HIIT in Pediatric Heart Transplant Recipients (MedBIKE™)
NCT05451979
Recruiting
Heart transplantation is the long-term treatment for children and adults with advanced heart failure. Post-transplant outcomes have improved over time, such that 50% of pediatric heart transplant recipients (HTR) remain alive with a need for re-transplantation 17-years following the initial transplant. With improved short- and medium-term outcomes, focus has shifted towards optimizing long-term survival and reducing transplant-associated morbidities. This includes strategies aimed at optimizing... Read More
Gender:
ALL
Ages:
Between 10 years and 18 years
Trial Updated:
02/03/2025
Locations: University of Alberta, Edmonton, Alberta
Conditions: Pediatric ALL, Transplant; Failure, Heart
Register for Updates
A2 to O Lung Transplants
NCT05581745
Recruiting
Blood group A2 to blood group O kidney and liver transplants have been shown to be safe and successful, especially in recipients with low pre-operative anti-A antibody titers and with the use of peri-operative antibody-depleting therapies. Since blood group O lung transplant candidates tend to have longer wait times and a higher waitlist mortality compared to other blood groups, we propose to conduct a prospective study of lung transplantation from blood group A2 donors to eligible blood group O... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Toronto General Hospital, University Health Network, Toronto, Ontario
Conditions: Lung Transplant, ABO Incompatibility
Register for Updates
The Efficacy of Intra-articular Triamcinolone Acetonide 5mg vs. 10 mg vs. 40 mg in Patients With Knee Osteoarthritis
NCT05806021
Recruiting
Osteoarthritis of the knee is a common problem that is increasing in prevalence as the population ages. In a knee with osteoarthritis, there is variable damage to the articular cartilage and underlying bone that can cause varying degrees of pain. When pain is bothersome, osteoarthritis is treated to improve functional abilities. One of the most recognized and used treatments is intra-articular cortisone injection. Cortisone is a powerful anti-inflammatory drug that is used to reduce pain. Unfo... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
02/03/2025
Locations: Centre Hospitalier Universitaire de Montréal - Hôtel-Dieu, Montréal, Quebec
Conditions: Primary Gonarthrosis
Register for Updates
RTMS and Steroid Joint Steroid Injection in Chronic Spinal Pain
NCT05840354
Recruiting
Chronic spinal pain (CSP) is one of the most common chronic pain conditions globally. Steroid joint injections (SJI) are a routine treatment option for patients with CLBP that is recalcitrant to other treatments. However, SJI has been shown to have limited long-term efficacy with patients often requiring another injection within months to adequately control pain. One option to prolong the analgesic effects of SJI is to use a type of noninvasive brain stimulation called repetitive transcranial ma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: St. Joseph's Health Care London, London, Ontario +1 locations
Conditions: Chronic Spinal Pain
Register for Updates
A Study of Selinexor Monotherapy in Subjects with JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
NCT05980806
Recruiting
The main purpose of this study with corresponding optional expansion is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and moderate thrombocytopenia based on spleen volume reduction (SVR). Additional efficacy and safety parameters will also be assessed during the study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: City of Hope - Duarte Main Site, Duarte, California +47 locations
Conditions: Myelofibrosis, Moderate Thrombocytopenia
Register for Updates